

# Dual-Energy Computed Tomography Has Additional Prognostic Value Over Clinical Measures in Gout Including Tophi: A Systematic Literature Review

Sally K. Stauder<sup>1</sup>  and Paul M. Peloso<sup>2</sup> 

**ABSTRACT. Objective.** This systematic literature review determined whether there is clinical utility for dual-energy computed tomography (DECT) to inform on prognosis for patients with gout. With DECT, individualized treatment plans could be developed based on the patient's unique urate burden, with DECT being used as a clinical outcome measure in gout management.

**Methods.** To evaluate DECT as a reliable, valid, and sensitive prognostic instrument, a librarian-assisted search was undertaken in PubMed and Embase for articles on gout and DECT informing on reliability; content, construct, and criterion validity; sensitivity to change; and minimum clinically important changes.

**Results.** This systematic literature review showed that DECT has high intra- and interrater reliability. Tophus burden correlates with functional loss to show content validity. DECT volume is positively correlated with death, cardiovascular risk factors, and the risk for future gout flares. DECT has excellent sensitivity to change with effective urate-lowering therapies.

**Conclusion.** DECT is a promising prognostic tool based on its high reliability, sensitivity to change, and emerging validity. Additional large, well-designed, prospective cohort studies are needed to fully evaluate its prognostic utility. This systematic review suggests that DECT very likely has additional prognostic information beyond clinical tophi assessment alone.

*Key Indexing Terms:* dual-energy computed tomography, flares, gout, monosodium urate, tophi, urate burden

Gout has a rising global prevalence, with the highest rates among the Pacific Island populations and a higher burden in the developed world; its regional prevalence varies from 0.1% up to 10.0%.<sup>1</sup> The United States has an estimated 9 million individuals with gout.<sup>2</sup> The current gold standard for a gout diagnosis is detection of monosodium urate (MSU) crystals in joint fluid.<sup>3</sup> Joint aspiration can be a painful, invasive process,<sup>4</sup> which not all healthcare providers are able to perform. Dual-energy computed tomography (DECT) scans are a noninvasive technique that may be an alternative diagnostic tool, especially in patients with more established gout,<sup>5</sup> as DECT scans have excellent reliability.<sup>6</sup>

The gout disease process is a continuum, starting with asymptomatic hyperuricemia, progressing to acute gouty attacks, and then to persistent arthritis, joint destruction, and subcutaneous tophi as urate deposits build.<sup>6</sup> Crystals can deposit in multiple

locations, including joints, tendons, cartilage, and skin.<sup>7</sup> Higher urate burdens are associated with diabetes, hypertension, cardiovascular (CV) disease, and chronic kidney disease.<sup>8-10</sup>

DECT scans provide an individualized volumetric urate burden and are a longitudinal outcome measure. DECT should be recommended as a standard clinical assessment if it can be proven to provide additional prognostic information beyond tophi counts alone. Tophi and DECT volumes are known independent predictors of mortality,<sup>11</sup> and DECT reliability is better than clinical tophi assessment.<sup>12</sup>

To have prognostic value, DECT should be reliable and valid, including content validity (ie, the results should represent the truth), construct validity (ie, the results should move in predictable ways with other clinical measures of similar concept, like erosions), and criterion validity (ie, the results should predict disease features, like death, disability, and distress). DECT should provide more prognostic information than clinical tophi alone to warrant routine clinical use. DECT should also be sensitive to change with effective urate-lowering therapy (ULT), with these changes correlating to other important health measures.<sup>13</sup> The goal of this systematic review is to inform on the reliability and validity of DECT to understand its prognostic value in patients with gout.

## METHODS

A systematic search was undertaken in PubMed and Embase databases from inception to February 29, 2022. Medical Subject Headings (MeSH) used for the search were as follows: ("dual energy computed tomography" OR

*This study was supported by Horizon Therapeutics plc, Deerfield, IL, USA. Horizon Therapeutics funded the collection of retrospective deidentified chart data and contributed to the analysis, data interpretation, and writing, review, and approval of the manuscript.*

<sup>1</sup>S.K. Stauder, BS, Florida State University College of Medicine, Florida State University, Tallahassee, FL; <sup>2</sup>P.M. Peloso, MD, FRCPC, Acelyrin, Inc, Los Angeles, California, USA.

PMP is a former employee of Horizon Therapeutics plc and holds company stock. SKS declares no conflicts of interest relevant to this article.

Address correspondence to Dr. P.M. Peloso, 1575 Winding Oaks Way, Naples, FL 34109, USA. Email: pmpeloso@gmail.com.

Accepted for publication June 30, 2022.

“DECT”) AND (“gout”) AND (“urate burden” OR “monosodium urate volume” OR “monosodium urate crystals”). The following keywords were used with the MeSH terms: (“dual energy computed tomography” OR “DECT”), (“gout, tophaceous gout, chronic gout”), and (“monosodium urate crystals” OR “monosodium urate burden” OR “tophi” OR “monosodium urate volume” OR “flares” OR “pain” OR “distress” OR “death” OR “disability” OR “function”). Titles and abstracts identified were screened by both authors. A manual search of secondary sources included personal holdings, conference abstracts, and review of the references of identified articles.

Inclusion criteria were original research on DECT and its reliability, validity, relationship to clinical outcomes, and ability to detect change. Participants must have had gout diagnosed by the American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification and/or crystal confirmation. Excluded papers included the following: editorials, narrative reviews, case reports, letters to the editor, and conference abstracts without complete methods and results. Nonhuman and non-English studies were excluded. Data selection and extraction were performed independently by both authors, and final data presentation was based on consensus.

To assess study quality, 2 approaches were implemented. For systematic reviews of DECT reliability, the AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews—revised) was used,<sup>14</sup> which was designed to critically appraise systematic reviews of randomized and nonrandomized studies based on 16 elements. An overall summary score is not provided, but each systematic review is rated based on weaknesses in critical domains. In the interest of space limitations, only the highest quality metaanalyses are represented in Table 1. For all other studies, we used the approach of the International League of Associations for Rheumatology 2000-2010 Decade of the Bone and Joint Neck Pain Task Force.<sup>15</sup> Methodological quality was evaluated by considering selection bias, information bias, and confounding to inform on a study’s internal validity. No formal grading scale was used. No articles were excluded based on predefined cut points. Methodologic features of the included studies are summarized in Table 1 and Table 2.

Reliability was interpreted based on generally accepted standards, such as intraclass correlation coefficient (ICC) estimates, where values of 0.00 to 0.39 represent poor agreement, 0.40 to 0.59 represent fair agreement, 0.60 to 0.74 represent good agreement, and 0.75 to 1.00 represent excellent agreement.<sup>16</sup> Validity was assessed by construct and criterion validity. Construct validity is described by OMERACT (Outcome Measures in Rheumatology) as follows: “Do the results of the instrument agree with expected results of other instruments measuring the same construct/concept?”<sup>17</sup> Criterion validity is described by OMERACT as follows: “Does the result of the instrument predict or correlate with long term outcomes (e.g. death, disability, perhaps X-ray damage)?”<sup>17</sup>

## RESULTS

MEDLINE and Embase searches yielded 393 potential citations. Full manuscripts of interest were retrieved and reviewed for 98 abstracts (24.9%). A total of 49 out of 98 manuscripts (50%) were found to be relevant to our goals. A complete list of articles considered, along with the rationale for final selections, is available from the authors. Articles on gout and DECT first appeared in English in 2007, denoting a nascent literature.

DECT is highly reliable, with excellent ICCs varying from 0.86 to nearly 1.00 for both intrarater and interrater reliability, as summarized in Table 1<sup>18-33</sup> along with DECT performance characteristics (ie, sensitivity, specificity, and area under the curve [AUC]). Systematic reviews of the highest quality are presented in descending order based on year of publication, followed by selected primary studies describing intrarater reliability and

then DECT studies in early gout showing the heterogeneity of DECT performance by gout duration.

Metaanalyses that scored the best on the AMSTAR 2 tool were authored by Gamala et al,<sup>19</sup> Chen et al,<sup>21</sup> Newberry et al,<sup>23</sup> Ogdie et al,<sup>24</sup> and Zhang et al.<sup>30</sup> The review by Ogdie et al<sup>24</sup> is among the oldest, and Newberry et al<sup>23</sup> included only 3 studies. The Gamala et al<sup>19</sup> and Chen et al<sup>21</sup> metaanalyses differ in their inclusion of studies with and without a joint aspiration gold standard. Chen et al<sup>21</sup> summarized 6 articles and showed a pooled sensitivity of 0.88 (95% CI 0.90-0.96), a pooled specificity of 0.85 (95% CI 0.67-0.78), and a pooled AUC of 0.93 (no 95% CI given), with joint aspiration used as the gold-standard assessment. Gamala et al<sup>19</sup> did not require joint aspiration to confirm gout in their included articles, and they included 10 articles with a pooled sensitivity of 0.81 (95% CI 0.77-0.86) and a pooled specificity of 0.91 (95% CI 0.85-0.95). In total, 2 studies that used aspiration for gout diagnosis had a pooled sensitivity of 0.92 (95% CI 0.81-0.97) and a pooled specificity of 0.81 (95% CI 0.69-0.90). A total of 2 studies using the ACR 1977 clinical criteria had a pooled sensitivity of 0.89 (95% CI 0.85-0.92) and a pooled specificity of 0.88 (95% CI 0.80-0.93), suggesting similar diagnostic performance with aspiration or clinical criteria.<sup>19</sup>

Singh and colleagues<sup>34</sup> studied a clinic-based cohort that confirms the comparable DECT test performance with either joint aspiration or a clinical diagnosis. In 147 patients with a mean gout duration of 9 years and a mean age of 65 years, DECT and ultrasound were contrasted against joint aspiration (ie, the gold standard) and ACR/EULAR 2015 clinical classification (ie, the silver standard).<sup>34</sup> DECT of feet and ankles had a sensitivity of 0.87 (95% CI 0.82-0.92) and a specificity of 1.00 (95% CI 1.00-1.00) vs joint aspiration. Against ACR/EULAR clinical criteria, DECT had a sensitivity 0.82 (95% CI 0.79-0.85) and a specificity 0.76 (95% CI 0.72-0.80), similar to joint aspiration. Singh et al<sup>34</sup> found that DECT of feet and ankles was only preferred to DECT of feet, ankles and knees combined, or knees alone, based on better AUCs. In fact, DECT of feet and ankles outperformed ultrasound against the gold standard of joint aspiration.

DECT in patients with early gout has lower sensitivity, as suggested by Gamala et al,<sup>19</sup> Ogdie et al,<sup>24</sup> Zhang et al,<sup>30</sup> and others. Zhang et al<sup>30</sup> examined patients with early gout (ie, < 1 year from first symptoms) and contrasted DECT sensitivity to patients with middle gout and late gout. DECT scans showed a sensitivity of 4 out of 15 (0.27) in early gout, 8 out of 12 (0.67) in middle gout, and 9 out of 10 (0.90) in late gout against joint aspiration.<sup>30</sup> Ultrasound sensitivity was higher in early-stage gout compared to DECT at 0.66 vs 0.27 ( $P < 0.050$ ).<sup>30</sup> For patients with early gout, Lee et al<sup>31</sup> showed sensitivities from 0.51 and 0.53 for 2 readers, with a specificity of 1.00 for both. Early gout was determined by excluding patients with tophi, erosions, or use of ULT, with 103 patients with 115 painful joints included, while DECT was read by 2 experienced radiologists. Gout diagnosis was based on consensus of 2 rheumatologists using the ACR/EULAR 2015 criteria. Kravchenko et al<sup>33</sup> suggested that early gout had more false negatives with DECT. Among 36 subjects, DECT confirmed that positive cases had a median

Table 1. Summary of the reliability and diagnostic performance characteristics of DECT imaging in patients with gout.

Authors, Year	Study Details	Study Selection and Raters	Intrater Correlation, ICC (95% CI)	Interrater Correlation, ICC (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	AUC (95% CI)
SLRs reporting on DECT reliability and diagnostic performance							
Shang et al, 2022 <sup>18</sup>	SLR; searched PubMed, Embase, Cochrane, Web of Science; included 13 DECT studies, 11 US studies	Selection by 2 independent reviewers; quality assessed by QUADAS-2; subjects had possible or established gout	NR	NR	Pooled 0.89 (0.80-0.94)	Pooled 0.91 (0.88-0.94)	Pooled 0.94 (0.92-0.96)
Gamala et al, 2019 <sup>19</sup>	SLR; searched PubMed, Embase, Cochrane Library; included 10 studies	1 reviewer screened titles, abstracts, and full text; final selection by consensus; data extracted in a standard format	NR	NR	Pooled 0.81 (0.77-0.86)	Pooled 0.91 (0.85-0.95)	Pooled 0.95 (0.93-0.97) at joint level; pooled 0.92 (0.81-0.95) at patient level
Yu et al, 2018 <sup>20</sup>	SLR; searched MEDLINE, PubMed, Embase, Cochrane Library; included 7 studies	2 investigators selected literature separately; > 1 reviewer performed data extraction	NR	NR	Pooled 0.88 (0.84-0.90)	Pooled 0.90 (0.85-0.93)	Pooled 0.95 (0.94-0.96)
Chen et al, 2017 <sup>21</sup>	SLR; searched Web of Science, PubMed, Elsevier, Wiley Online, Cochrane Library, 2005-02/2016; included 11 studies, 6 of DECT, 6 of US, 1 of both	Data extraction and quality assessed by 2 independent investigators; consensus used for disagreement	NR	NR	Pooled 0.88 (0.90-0.96)	Pooled 0.85 (0.67-0.78)	Pooled 0.93; 95% CI not given
Lee and Song, 2017 <sup>22</sup>	SLR; searched MEDLINE, Embase, Cochrane Library to Oct 2016, reference lists reviewed; included 8 DECT studies	2 data extractors and consensus used for discrepancies	NR	NR	Pooled 0.84 (0.81-0.87)	Pooled 0.93 (0.93-0.96)	Pooled 0.95 (0.94-0.96)
Newberry et al, 2017 <sup>23</sup>	PRISMA guidelines followed; 2014 AHRQ protocol	3 studies on DECT evaluating 235 patients from 3 academic institutions	NR	NR	0.85-1.00; 2 studies suggest early gout lower vs later gout; 95% CIs not given	0.82-0.93; 95% CIs not given	NR
Ogdie et al, 2015 <sup>24</sup>	SLR; included only studies using gold standard by crystals; included 11 studies in secondary care; mean gout duration ~ 7 yrs	2 authors extracted data using standard tool; QUADAS tool used by 2 reviewers; a third reviewer settled discrepancies	NR	NR	Pooled 0.87 (0.79-0.93)	Pooled 0.84 (0.75-0.90)	Pooled 0.90; 95% CI not given
Studies reporting on intrater and interrater reliability ICCs							
Bayat et al, 2016 <sup>25</sup>	224 patients, 182 without gout; 70.0% males; mean age 61 yrs; mean gout duration 9 yrs	DECT scans scored by 2 independent readers; rheumatology fellow with no DECT experience and experienced rheumatologist	0.99 (0.98-1.00)	0.98 (0.97-0.98)	NR	NR	NR
Shi et al, 2015 <sup>26</sup>	66 patients; median age 52 yrs; 92.0% males; median gout duration 7 yrs (range 1-30)	2 independent observers measured tophus volumes and bone erosions using automated software	1.00 (1.00-1.00)	1.00 (1.00-1.00)	NR	NR	NR

Authors, Year	Study Details	Study Selection and Raters	Intrareater Correlation, ICC (95% CI)	Interrater Correlation, ICC (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	AUC (95% CI)
Choi et al, 2012 <sup>27</sup>	80 participants: 40 with gout, 40 without; gout patients mean age 62 yrs; 89.0% males; mean BMI 30	Blinded radiologists read DECT with automated software; interrater ICC of 2 independent radiologists on 17 patients	1.00 (1.00-1.00)	1.00 (1.00-1.00)	0.78 (0.62-0.89); excludes 3 patients	0.93 (0.80-0.98)	NR
Pascart et al, 2017 <sup>28</sup>	64 patients, 34 with ≥ 1 tophi on US; mean age 65 yrs; 84.0% males; mean gout duration 13 yrs	Patients with gout prospectively recruited to assess urate deposition on US and DECT; images read by 2 radiologists	NR	1.00 (1.00-1.00) for urate deposition in knees and feet; 0.69 (0.47-0.83) for tophi	NR	NR	NR
Dalbeth et al, 2012 <sup>29</sup>	25 gout patients; median age 64 yrs; 92.0% males; median gout duration 24 yrs	2 independent observers read DECT	1.00 (0.99-1.00)	0.95 (0.92-0.97)	NR	NR	NR
Studies reporting on early gout and DECT diagnostic performance							
Zhang et al, 2020 <sup>30</sup>	41 consecutive patients suspected of gout; 37 had crystal confirmation; 15 had early gout (< 1 yr), 12 had midstage gout, (1-3 yrs), 10 had late gout (> 3 yrs)	DECT after joint aspiration; a single experienced DECT radiologist read images blinded to aspiration; dual-source CT scanner (Siemens) using Gout Syngo software	NR	NR	Early gout, 0.27; middle gout, 0.75; late gout, 0.90; 95% CIs not given	NR	NR
Lee et al, 2019 <sup>31</sup>	67 gout patients with 72 involved joints, diagnosed by 2 rheumatologists using ACR/EULAR 2015 criteria; controls were 36 non-gout patients with 43 involved joints	2 experienced MSK radiologists read DECT on first-generation Somatom Definition 64 (Siemens); 4-point scale used to remove artifacts; scores ≥ 3 considered positive	NR	0.95; 95% CI not given	Reader 1, 0.53; reader 2, 0.51; 95% CIs not given	1.00 for both readers; 95% CIs not given	Reader 1, 0.77; reader 2, 0.82; 95% CIs not given
Shang et al, <sup>a</sup> 2021 <sup>32</sup>	196 patients included; mean age 55 yrs; mean disease duration 6 yrs; 89.0% males; tophi in 17.0%	2 blinded MSK radiologists read DECT independently; 1 deposit in 1 joint sufficient for gout diagnosis	NR	NR	Early gout, 0.38 (0.18-0.62); middle gout, 0.63 (0.42-0.81); late gout, 0.78 (0.68-0.85)	Early gout, 0.96 (0.82-1.00); middle gout, 1.00 (0.54-1.00); late gout, 0.88 (0.62-0.98)	Early gout, 0.97 (0.52-0.80); middle gout, 0.82 (0.64-0.93); late gout, 0.83 (0.74-0.89)
Kravchenko et al, 2022 <sup>33</sup>	36 of 42 patients in analysis; mean age 61 yrs, 92.0% males; mean symptom duration 20 mos	2 blinded DECT readers with 3 and 4 years' experience; arthrocentesis and synovial fluid analysis by rheumatologist; US by board-certified MSK sonographer	NR	NR	0.63 (0.41-0.81)	0.92 (0.62-1.00)	NR

<sup>a</sup> DECT performance results and pooled results across 2 different single-source DECT devices: Discovery CT and Revolution CT. ACR: American College of Rheumatology; AHRQ: Agency for Healthcare Research and Quality; AUC: area under the curve; CT: computed tomography; DECT: dual-energy computed tomography; EULAR: European Alliance of Associations for Rheumatology; ICC: intraclass correlation coefficient; MSK: musculoskeletal; NR: not reported; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; QUADAS: Quality Assessment of Diagnostic Accuracy Studies; SLR: systematic literature review; US: ultrasound.



Table 2A. Death and predictors of mortality.

Authors, Year	Study Design	Population	Follow-up	Outcomes
Marry-Ané et al, 2021 <sup>41</sup>	Prospective cohort; baseline DECT of knees alone and of ankles and feet with clinical assessment; cardiovascular and metabolic events captured; univariate and multivariate Cox regression models used to determine HRs for mortality risk	128 subjects; mean age 66 (SD 14) yrs and 87.0% males; mean gout duration 8 yrs	Follow-up visits at 1, 2, and 3 years based on phone calls to patients; assessment of laboratory values; to confirm mortality, medical records were searched, and phone calls were made to general practitioners	DECT volume and SUA were the only predictors of all-cause mortality; DECT volume univariate HR 1.02 (95% CI 1.01-1.03; $P = 0.004$ ); DECT volume multivariate analysis HR 1.02 (95% CI 1.00-1.03; $P = 0.020$ )
Pascart et al, 2020 <sup>10</sup>	Cross-sectional study; DECT scans of knees alone and of feet and ankles; gout diagnosed by 2015 ACR/EULAR criteria in 3 French hospitals; patients were not previously exposed to ULT	91 patients; mean age 63 (SD 16) yrs; mean gout duration 7 (SD 10) yrs; 83.5% males	Consecutive patients during a first medical consultation with gout diagnosis and no prior ULTs enrolled; demographic, gout history, comorbidities, and biological data collected; association with DECT volume analyzed in bivariate and multivariate analyses	Bivariate analysis, median DECT volume (IQR) for patients with clinical tophi was 2.68 (IQR 0.71-6.33) $\text{cm}^3$ vs without tophi was 0.43 (IQR 0.12-1.90) $\text{cm}^3$ ( $P = 0.004$ ); median DECT volume for gout duration of > 2 years was 1.01 (IQR 0.22-3.00) $\text{cm}^3$ and for < 2 years was 0.25 (IQR 0.10-0.70) $\text{cm}^3$ ( $P = 0.007$ ); median DECT volume with hypertension OR was 1.01 (IQR 0.18-2.66) vs without was 0.38 (IQR 0.10-0.62; $P = 0.020$ ); Diabetes mellitus DECT volume HR 1.09 (IQR 0.29-2.63) vs without 0.41 (IQR 0.09-2.11; $P = 0.050$ ); CHF DECT volume HR 2.04 (IQR 0.70-2.95) vs without 0.42 (IQR 0.12-1.96; $P = 0.030$ ); CHF was retained as an explanatory factor for DECT volume, in multivariate analysis, coefficient 7.13, standard error 2.99 (95% CI -2.32 to 16.36), adjusted $R^2 = 0.21$ ; $F = 5.60$ ; $P = 0.0002$
Gamala et al, 2020 <sup>42</sup>	Cross-sectional study of gout patients diagnosed by 2015 EULAR/ACR classification who underwent DECT scan; Dutch risk prediction SCORE and CVD FRS values calculated	68 patients with mean age 61 (SD 14) yrs; 84.0% males	History and physical exam and DECT were taken within 6 months of initial joint aspiration; bivariate and multivariate relationships explored on logistic regression	Multiple logistic regression showed a positive, nonsignificant trend between abnormal DECT scores and higher CVD event predictions; comparing DECT volumes between the first and third quartiles, OR 4.80 (95% CI 0.60-42.00; $P = 0.100$ ); comparing first and fourth quartiles, OR 6.40 (95% CI 0.70-63.00; $P = 0.100$ )
Perez-Ruiz et al, 2014 <sup>40</sup>	Prospective clinical cohort study; DECT was not assessed; clinical tophi reported on examination	706 patients enrolled with mean age 58 (SD 12) yrs; 94.0% males; mean gout duration 6 (SD 6) yrs	Baseline evaluation and follow-up over 3 to 12 months with mean follow-up duration of 47 (SD 46) months (range 1-204); SMRs assessed magnitude of excess mortality among gout patients vs general population	Cox regression (unadjusted) analysis for tophi versus no tophi, HR 2.39 (95% CI 1.50-3.80); multivariate (adjusted) analyses for presence vs absence of tophi, HR 2.05 (95% CI 1.29-3.28); tophi remained significant for mortality risk after adjustment for baseline SUA values (HR 1.98, 95% CI 0.24-3.20)

Authors, Year	Study Design	Population	Follow-up	Outcomes
Gamala et al, 2018 <sup>8</sup>	Retrospective clinical analysis of all adult patients with DECT imaging from January 2013 to December 2014; DECT assessed by MSK radiologist	147 patients with mean age 63 (SD 2) yrs; 68.0% males; mean gout disease duration 3 (SD 7) yrs	Cross-sectional analysis, no follow-up; Variables with $P < 0.10$ in univariate analyses brought into multivariate models; DECT result as positive or negative was the outcome variable	Multivariable regression model showed the following: CVD (OR 3.07, 95% CI 1.26-7.47), gout duration (OR 1.01, 95% CI 1.00-1.02), frequency of attacks (OR 1.23, 95% CI 1.07-1.42), and creatinine clearance (OR 2.03, 95% CI 0.91-1.00), all independently associated with positive DECT scans
Pascart et al, 2018 <sup>4</sup>	Cross-sectional study; DECT in knees and feet; ACC CVD risk scores (FRS) calculated over 10-yr horizon	42 patients with mean age 63 (SD 13) yrs; 95.0% males; 33/42 without prior CAD, PAD, or CVA	No follow-up; relationship between DECT and risk factors examined by correlation coefficients	Correlations between DECT volumes in knees alone, feet alone, and in knees and feet, and CVD FRS values were poor, at -0.12, -0.08, and 0.11, respectively; all $P$ values $> 0.050$
Vincent et al, 2017 <sup>11</sup>	Prospective cohort study of early gout, with duration of $< 10$ yrs; Clinical tophi assessed; no DECT captured; follow-up $\geq 1$ yr	295 subjects with mean age 59 (SD 15) yrs; 71.0% males; mean gout duration 5 (SD 3) yrs	Mean follow-up 5 (SD 2) yrs with a 1-year minimum on all; SMRs compared to the general population and Cox proportional hazard risk models calculated	14.6% died at study end; SMR 1.96 (95% CI 1.44-2.62); clinical tophi only baseline variable independently associated with CVD death (HR 3.13, 95% CI 1.38-7.10) and non-CVD death (HR 3.48, 95% CI 1.25-9.63)
Lee et al, 2018 <sup>13</sup>	Retrospective cohort study; DECT in 91 gout patients; Mean DECT volume for positive DECT scans was 8.10 (SD 21.00) $\text{cm}^3$	91 patients: 55 with positive DECT; 36 with negative DECT; all 13 patients with clinical tophi were DECT positive; mean age 48 (SD 15) yrs; 98.0% males; mean gout duration 5 (SD 5) yrs	No follow-up; 10-year cardiovascular risk estimated with FRS	FRS was 2.8 times higher in patients with positive DECT in the highest quartile compared to lowest DECT quartile (24.7% vs 8.7%, $P = 0.024$ ); multivariable linear regression showed DECT volume was an independent determinant of total CVD FRS, total $R^2 = 0.76$ , $P < 0.001$

ACC: American College of Cardiology; ACR: American College of Rheumatology; CAD: coronary artery disease; CHF: chronic heart failure; CVA: cerebrovascular accident; CV: cardiovascular; CVD: cardiovascular disease; DECT: dual-energy computed tomography; EULAR: European Alliance of Associations for Rheumatology; FRS: Framingham Risk Score; HR: hazard ratio; MSK: musculoskeletal; NR: not reported; OR: odds ratio; PAD: peripheral arterial disease; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SCORE: Systematic Coronary Risk Evaluation; SMR: standardized mortality ratio; SUA: serum uric acid; ULT: urate-lowering therapy.

Table 2B. Disability.

Authors, Year	Study Design	Population	Follow-up	Outcomes
Dalbeth et al, 2007 <sup>39</sup>	Prospective clinical cohort in unselected rheumatology patient clinic	20 participants with initial baseline assessment; hand function assessed on Sollerman hand function test, DASH instrument, fingertip to palm distance, and grip strength; number of tophi on hands counted and position recorded	Data were analyzed cross-sectionally, both univariate and multiple linear regression	Number of joints with tophi was the best predictor of the Sollerman hand function in both univariate analyses ( $r^2 = 0.59$ ) and multivariate analyses ( $F = 3.94$ , $r^2 = 0.81$ , $P = 0.024$ ); hand tophi joint count also correlated with hand disability on the DASH instrument ( $r = 0.77$ , $P < 0.0001$ ); tophus counts and flares correlated over prior 6 months ( $r = 0.63$ , $P < 0.003$ )

DASH: Disabilities of Arm, Shoulder, and Hand.

disease duration of 43 (IQR 5-103) months, whereas false negatives had a median duration of 4 (IQR 2-33) months.<sup>33</sup> Shang et al<sup>18</sup> defined early gout as a disease duration of less than 1 year, middle gout as a duration from 1 to 3 years, and late gout as a duration of more than 3 years in a 196-subject cross-sectional study. The 49 early gout cases had a DECT sensitivity (feet and ankles) of 0.38 (95% CI 0.18-0.62), with a specificity of 0.96 (95% CI 0.82-0.99); late gout had a sensitivity of 0.78 (95% CI 0.68-0.85) and a specificity 0.88 (95% CI 0.84-0.99).<sup>32</sup> DECT reliability was not influenced by gout duration, with interreader agreements of 0.87 and 0.86 in early gout and late gout, respectively.<sup>32</sup> In a separate study, Shang et al<sup>18</sup> performed a metaanalysis of 28 studies with DECT and ultrasound, including early gout, defined as disease duration of less than 2 years. The DECT pooled sensitivity in early gout was 0.75 (95% CI 0.60-0.86) and the pooled specificity was 0.85 (95% CI 0.75-0.91); ultrasound had a pooled sensitivity of 0.93 (95% CI 0.72-0.99) and a pooled specificity of 0.80 (95% CI 0.71-0.86) when positive findings included the double contour sign and ultrasound detected tophi.<sup>18</sup> DECT was a better diagnostic test overall compared to ultrasound when all disease durations were combined; the DECT pooled sensitivity was 0.89 (95% CI 0.80-0.94) and the pooled specificity was 0.91 (95% CI 0.88-0.94), as compared to the ultrasound pooled sensitivity of 0.84 (95% CI 0.73-0.91) and the pooled specificity of 0.84 (95% CI 0.78-0.89).<sup>18</sup> Collectively, early-stage gout appears to have reduced sensitivity (ie, more false negatives) with preserved specificity (ie, fewer false positives) compared to later gout.

Construct validity for DECT was demonstrated by its correlation with radiographic erosions in 4 studies.<sup>35-38</sup> Dalbeth et al<sup>35</sup> reported a cross-sectional study of 92 patients with tophaceous gout undergoing radiographs and DECT of feet. An experienced rheumatologist scored 920 metatarsophalangeal (MTP) joints. DECT volume was correlated to radiographic damage, with a correlation coefficient of 0.70 ( $P < 0.001$ ).<sup>35</sup> Shi et al<sup>36</sup> studied 27 patients with gout in a retrospective cross-sectional study; the patients had a median age of 52 years and a median disease duration of 84 months. Total erosions were defined on computed tomography (CT) as a focal area of cortex loss with sharply defined margins in 2 planes and bone cortex breach in more than 1 plane. Total erosions, defined as above, positively correlated with DECT volume ( $r_s = 0.55$ ,  $P = 0.003$ ) in 52 individual foot joints across all participants.<sup>36</sup> Pecherstorfer et al<sup>37</sup> studied 20 patients with gout with a mean age of 59 years and a mean gout duration of 12 years. The MTP1 joint, the phalangeal base, and 2 sesamoid bones were assessed by DECT and CT. Erosions were defined as pathological juxtaarticular cortical breaks in at least 2 successive slices and vertical planes on CT. DECT volume correlated with erosions ( $r = 0.60$ ,  $P = 0.005$ ).<sup>37</sup> Yokose et al<sup>38</sup> studied 153 patients with a mean age of 59 years and a mean disease duration of 15 years. DECT and CT scans of the hands and wrists, feet and ankles, and knees alone showed that subcutaneous tophi were more likely when bone erosions were present (83.0% vs 67.0%,  $P = 0.040$ ), with erosions 8 times more likely with abnormal DECT scans of the ankles and feet vs normal DECT scans (43.6% vs 8.6%, odds ratio [OR] 8.10).<sup>38</sup>

Table 2C. Distress, as assessed by gout flares.

Authors, Year	Study Design	Population	Follow-up	Outcomes
Dalbeth et al, 2019 <sup>45</sup>	Cross-sectional analysis nested in 2-year randomized trial; 1 group received allopurinol dose escalation to SUA target (< 6 mg/dL) from start; the second received conventional dosing for 1 year with dose adjustments after 1 yr	87 participants; mean age 60 (SD 13) yrs; 92.0% males; mean gout duration 19 (SD 14) yrs	DECT was performed at baseline, year 1, and year 2	DECT volumes were higher at 1 and 2 yrs in those without SUA control; at yr 1, DECT volumes were 0.62 cm <sup>3</sup> in patients without SUA control vs 0.46 cm <sup>3</sup> with SUA control; at yr 2, DECT volumes were 0.77 cm <sup>3</sup> in patients without SUA control vs 0.20 cm <sup>3</sup> with SUA control; gout flares at yr 2 showed DECT volume with flares of 2.60 cm <sup>3</sup> (95% CI 2.30-3.00) vs 2.10 cm <sup>3</sup> (95% CI 2.00-2.20) without flares ( <i>P</i> < 0.001)
Dalbeth et al, 2018 <sup>12</sup>	Prospective cohort study; patients treated with allopurinol > 300 mg/day for > 3 months prior to entry; DECT of hands and wrists, feet/ankles/Achilles and knees bilaterally done within 28 days; patients from 9 USA centers and 1 NZ center	223 patients eligible, 153 patients with interpretable DECT, 152 in analyses; central DECT reading in Vancouver, Canada; adults (18-85 yrs), all met ARA criteria for gout; approximately 25.0% had palpable tophi and 50.0% had elevated SUA levels	Analysis was correlational; relationship of DECT volume against clinical variables examined; no multivariable analysis	83.3% of patients with abnormal DECT scans had flares in past 3 months vs 63.6% with abnormal DECT scans but no flares ( <i>P</i> = 0.019); greater DECT volume associated with the following: 1) SUA levels ≥ 6 mg/dL; 2) > 1 gout flare; 3) allopurinol dose > 300 mg/day; DECT abnormal in 46.9% of patients with SUA < 6.0 mg/dL and no palpable tophi, and up to 90.0% for those with SUA > 6.0 mg/dL and palpable tophi; DECT volume increased with increasing tophi counts
Gamala et al, 2018 <sup>8</sup>	Retrospective clinical analysis of all adult patients with DECT imaging from January 2013 to December 2014; DECT assessed by MSK radiologist	147 patients with mean age 63 (SD 2) yrs; 68.0% males; mean gout disease duration 3 (SD 7) yrs	Cross-sectional analysis, no follow-up; variables with <i>P</i> < 0.100 in univariate analyses brought into multivariate models; DECT result as positive or negative was the outcome variable	Multivariable regression model showed CVD (OR 3.07, 95% CI 1.26-7.47), gout duration (OR 1.01, 95% CI 1.00-1.02), frequency of attacks (OR 1.23, 95% CI 1.07-1.42), and creatinine clearance (OR 2.03, 95% CI 0.91-1.00) to all be independently associated with positive DECT scans
Pascart et al, 2018 <sup>46</sup>	Cohort study recruited gout patients; urate burden assessed by DECT and US	36 of 78 patients had all assessments, including DECT performed; mean age of 64 (SD 14) yrs; 87.0% males; mean gout duration 12 (SD 12) years; mean number of flares reported over past 12 months 4.10 (SD 1.30)	Patients followed up at 3, 6, and 12 months; univariate and multivariate analyses using logistic regression	At 6 months on univariate analysis, factors associated with flare risk ( <i>P</i> ≤ 0.100) were as follows: 1) hypertension: patients without flare = 22 (66.7%) vs patients with ≥ 1 flare = 5 (26.3%), chi-square, <i>P</i> = 0.012; 2) gout duration: patients without flare, mean 10 (SD 11) yrs vs patients with ≥ 1 flare, mean 15 (SD 13) yrs, <i>t</i> test, <i>P</i> = 0.061; 3) DECT volume in feet: patients without flare, mean 0.90 (SD 1.30) cm <sup>3</sup> vs patients with at least 1 flare, mean 2.40 (SD 2.1) cm <sup>3</sup> , <i>t</i> test, <i>P</i> = 0.006; 4) subcutaneous tophi: patients without flare, <i>n</i> = 7 (21.2%) vs patients with at least 1 flare, <i>n</i> = 9 (47.4%), chi-square, <i>P</i> = 0.098; On multivariable analysis, DECT volume was the only predictor of flares; DECT volume at feet with flares, mean 2.10 (SD 1.9) cm <sup>3</sup> vs with no flares, mean 0.9 (SD 0.08) cm <sup>3</sup> , <i>P</i> = 0.050; flare risk was 2.03 times greater for each 1.00-cm <sup>3</sup> increase in DECT volume in feet

ARA: American Rheumatism Association; CVD: cardiovascular disease; DECT: dual-energy computed tomography; MSK: musculoskeletal; NZ: New Zealand; OR: odds ratio; SUA: serum uric acid; US: ultrasound.






Figure. Criterion validity for DECT in patients with gout based on stage of gout, with and without tophi and with and without DECT for death and mortality prediction, disability, and distress (ie, gout flares). DECT: dual-energy computed tomography.

Importantly, DECT has been shown to detect urate deposition in patients without clinical evidence of urate abnormalities. Dalbeth et al<sup>12</sup> collected DECT scans from 152 patients with and without palpable tophi. Patients were treated with allopurinol doses of > 300 mg/day for 5 years, and DECT of the hands and wrists; feet, ankles, and Achilles; and knees alone were collected. DECT abnormalities were present in 47.0% of patients with normal serum uric acid (< 6.0 mg/dL) without palpable tophi, and this increased to 90.0% when serum uric acid was > 6.0 mg/dL and tophi were palpable.<sup>12</sup> Therefore, DECT volume correlates with bone erosions, whereas DECT deposits exist in the absence of clinical urate abnormalities.

Evidence for criterion validity is summarized in the Figure and in Table 2A-C. Dalbeth et al<sup>39</sup> found that tophaceous joint disease strongly predicts loss of hand function. The number of joints with overlying tophi was found to be the single best predictor of Sollerman hand function, with a correlation coefficient of 0.59 ( $P < 0.050$ ).<sup>39</sup> No studies have examined DECT volume against hand or foot function or overall disability, but since joint erosions are a direct consequence of tophus invasion, such a relationship would be expected.<sup>35</sup>

Perez-Ruiz et al<sup>40</sup> studied a large clinical cohort and found that patients with gout with an increasing burden of clinical tophi had a proportional increased risk of death (hazard ratio [HR] 2.05, 95% CI 1.29-3.28). Vincent et al<sup>11</sup> found that clinical tophi were the best predictors of all-cause and CV mortality in patients with gout. Greater urate deposition on DECT also correlates with mortality and predictors of CV mortality.

Marty-Ané et al<sup>41</sup> followed a cohort of 128 patients with gout for 3 years; the cohort had a mean age of 66 (SD 14) years and a mean gout duration of 11 (SD 10) years. Baseline DECT scans of feet, ankles, and knees showed that DECT volumes were the single best predictor of mortality (HR 1.02, 95% CI 1.01-1.03).<sup>41</sup> Survivors had smaller DECT volumes, on average, as compared to nonsurvivors (0.20 vs 0.40 cm<sup>3</sup>,  $P = 0.045$ ); in addition, DECT volume was associated with mortality, but baseline clinical tophi were not ( $P = 0.060$ ).<sup>41</sup> DECT volume and predictors of CV mortality were assessed in 6 studies, with 5 reporting a positive association.<sup>8,10,41-43</sup> A retrospective cross-sectional study by Gamala et al<sup>8</sup> reported that a positive DECT scan was associated with the presence of CV disease (OR 3.07, 95% CI 1.26-7.47).

A 2020 study by Gamala et al<sup>42</sup> showed a positive, nonsignificant relationship using multivariate logistic regression between positive DECT volume and predicted CV events; ORs for mortality risk increased as DECT volume increased, from the first to the third quartile (OR 4.80, 95% CI 0.60-42.00;  $P = 0.100$ ) and from the first to the fourth quartile (OR 6.40, 95% CI 0.70-63.00;  $P = 0.100$ ). Lee et al<sup>43</sup> performed a clinical case study and found a significant univariate association between DECT volume and the American Heart Association 10-year CV risk score ( $r = 0.22$ ,  $P = 0.040$ ). A multivariable analysis showed DECT scores to be one of the strongest predictors (total model fit  $R^2 = 0.76$ ,  $P < 0.001$ ).<sup>43</sup> Pascart et al<sup>44</sup> initially found no significant association between DECT volumes of the knees, feet, or both and CV risk on the Framingham Risk Score, with  $P$  values of 0.180, 0.010, and 0.130, respectively.

In a second study, Pascart et al<sup>10</sup> studied 91 patients with gout who were not previously on ULT with baseline DECT scans of the feet, ankles, and knees. DECT volumes of  $\geq 1 \text{ cm}^3$  were statistically associated with CV risk factors, including age, gout duration, clinical tophi, hypertension, diabetes, and chronic heart failure.<sup>10</sup> The median DECT volumes were 1.01 (IQR 0.18-2.66)  $\text{cm}^3$  for patients with hypertension and 0.38 (IQR 0.10-0.62)  $\text{cm}^3$  for those without ( $P = 0.020$ ). For diabetes, the median DECT volumes were 1.09 (IQR 0.29-2.63)  $\text{cm}^3$  for patients with diabetes vs 0.41 (IQR 0.09-2.11)  $\text{cm}^3$  for those without ( $P = 0.050$ ). The median DECT volumes were 2.04 (IQR 0.70-2.95)  $\text{cm}^3$  for patients with chronic heart failure vs 0.42 (IQR 0.12-1.96)  $\text{cm}^3$  for those without ( $P = 0.030$ ).<sup>10</sup> The median DECT volumes were 1.01 (IQR 0.22-3.00)  $\text{cm}^3$  for those with a gout disease duration of  $> 2$  years vs 0.25 (IQR 0.10-0.70)  $\text{cm}^3$  for those with a disease duration of  $\leq 2$  years ( $P = 0.007$ ). In multivariable analysis, chronic heart failure was retained as a factor explaining DECT volume (adjusted  $R^2 = 0.21$ ,  $F = 5.60$ ,  $P = 0.0002$ ). Thus, DECT volume has been associated with CV mortality in a prospective cohort,<sup>41</sup> with predictors of CV mortality in 5 out of 6 studies.

Criterion validity includes the concept of distress, with measures including pain and disability associated with gout flares. Gout flare rates were shown to be positively correlated to DECT volume in 4 studies.<sup>8,12,45,46</sup> Dalbeth et al<sup>45</sup> followed patients over 2 years and found that those with flares had mean DECT volumes of 2.60 (95% CI 2.30-3.00)  $\text{cm}^3$  vs 2.10 (95% CI 2.00-2.20)  $\text{cm}^3$  among those without flares ( $P < 0.001$ ). Pascart et al<sup>46</sup> found that DECT volume predicted future gout flares. Patients with  $\geq 1$  flare between 0 and 6 months had a mean DECT volume of 2.40 (SD 2.1)  $\text{cm}^3$  vs those without flares whose mean DECT volume was 0.90 (SD 1.30)  $\text{cm}^3$  ( $P = 0.006$ ).<sup>46</sup> Dalbeth et al<sup>12</sup> demonstrated that 83.3% of patients with abnormal DECT scans had flares in the past month, as compared to 63.6% of patients with abnormal DECT scans who did not have flares ( $P = 0.019$ ). Greater DECT volumes were associated with more palpable tophi, serum urate levels  $\geq 6 \text{ mg/dL}$ ,  $> 1$  gout flare, and allopurinol doses of  $> 300 \text{ mg/day}$ .<sup>12</sup> A retrospective analysis by Gamala et al<sup>8</sup> showed that a positive DECT scan was associated with more gouty attacks per year (OR 1.23, 95% CI 1.07-1.42) compared to patients without abnormal DECT scans.

DECT is sensitive to changes in urate volumes. Araujo and colleagues<sup>47</sup> measured the tophus volume on DECT before and after pegloticase intravenous treatments. A clinical cohort study of 152 patients with gout assessed DECT of the hands, wrists, feet, ankles, and knees. The mean DECT volume pretreatment was 9.15  $\text{cm}^3$ , and the mean DECT volume posttreatment, after a mean of 12 months, was 1.89  $\text{cm}^3$ , representing a 95% reduction.<sup>47</sup> Modjinou et al<sup>48</sup> showed that DECT scans detected a 100% resolution of urate deposition in 3 index tophi over 6 months in a single-patient clinical study. Oral ULT was shown to reduce the DECT urate burden in 4 prospective studies.<sup>45,49-51</sup>

In a study with 29 patients with tophaceous gout, Chui et al<sup>49</sup> demonstrated that DECT volume declined from a mean of 10.94 (SD 10.59)  $\text{cm}^3$  at baseline to a mean of 2.87 (SD 5.27)

$\text{cm}^3$  after being on allopurinol therapy for a mean of 20 months ( $P < 0.001$ ), representing a 75.0% reduction. When serum urate values were  $> 0.43 \text{ mM/L}$  (7.00 mg/dL), dissolution times approached infinity; when serum urate values approached zero, DECT dissolution was modeled to take 4 to 8 months.<sup>49</sup> In the NOR-Gout (Gout in Norway) 2-year clinical cohort study, DECT of the feet and ankles was measured in 187 patients diagnosed by aspiration.<sup>50</sup> The patient sample was 95.0% male with a mean age of 57 years, a mean disease duration of 8 years, and a mean baseline serum urate of 501 (SD 80) mM/L.<sup>50</sup> Using allopurinol and febuxostat in a treat-to-target approach, mean serum urate values declined to 311 (SD 48) mM/L at 12 months and to 322 (SD 67) mM/L at 24 months. The percentage of patients with clinical tophi declined from 16.6% at baseline to 11.3% at 1 year and to 9.1% at 2 years; DECT volumes declined in parallel, with study-specific DECT scoring at 1 year and 2 years ( $P < 0.010$  for both). Dalbeth et al<sup>45</sup> studied patients receiving allopurinol in a randomized trial comparing immediate titration to maintain serum urate of  $< 0.36 \text{ mM/L}$  to standard allopurinol dosing for 1 year then titration from year 1 to 2. DECT of the feet and ankles was read by 2 independent readers who were blind to treatment; DECT was evaluated in 87 subjects at baseline and at year 2. There was a substantial reduction in serum urate, with  $> 69.0\%$  of patients reaching serum urate targets of  $< 0.36 \text{ mM/L}$ , with DECT volume declining over 20.0% across the 2 years ( $P < 0.001$ ).<sup>45</sup> Sun et al<sup>51</sup> studied 44 patients with gout who were treated with allopurinol or febuxostat with or without probenecid. Among 42 men and 2 women with a gout duration between 1 and 9 years, baseline and follow-up DECT scans of the feet were obtained up to 24 months after baseline. In concert with serum urate decreases from a mean value of 516  $\mu\text{M/L}$  to 360  $\mu\text{M/L}$ , DECT volumes decreased approximately 50.0% from baseline ( $P < 0.020$ ); treatment duration was a significant predictor of DECT resolution ( $P < 0.010$ ).<sup>51</sup>

Limited information is available on the definition of a clinically important DECT volume. Pascart et al<sup>10</sup> estimated the minimum DECT volume related to excess mortality risk in patients with a disease duration of 11 years; in that study, they showed that survivors had a mean DECT volume of 0.20  $\text{cm}^3$ , whereas nonsurvivors had a mean DECT volume of 0.40  $\text{cm}^3$ . They also reported that DECT volumes  $> 1 \text{ cm}^3$  predicted a higher burden of comorbid conditions (AUC = 0.84). The 1- $\text{cm}^3$  threshold separated patients with gout into groups with and without hypertension, diabetes, and chronic heart failure.<sup>10</sup> Pascart et al<sup>46</sup> showed that DECT volume was related to future gout flares; mean DECT volumes were 2.40 (SD 2.10)  $\text{cm}^3$  for patients with  $\geq 1$  flare and 0.90 (SD 1.30)  $\text{cm}^3$  among those without flares ( $P = 0.006$ ). From these results, the authors suggested that the minimum DECT volume predicting flares was 0.81  $\text{cm}^3$ . Dalbeth et al<sup>45</sup> found that patients with flares over a 2-year interval had a mean DECT volume of 2.60  $\text{cm}^3$  (95% CI 2.30-3.00) as compared to those without flares who had a mean DECT volume of 2.10  $\text{cm}^3$  (95% CI 2.00-2.20;  $P < 0.001$ ). Thus, a DECT volume difference of 0.50  $\text{cm}^3$  may be important at a population level. Rajan et al<sup>52</sup> has shown that the smallest detectable difference in DECT of the feet over 12 months is 0.91

cm<sup>3</sup>. Since the minimum important volume of DECT must be larger than the smallest detectable difference, a value of 1.00 cm<sup>3</sup> is tentatively proposed as the minimum important difference for DECT. The minimum clinically important DECT volume for improvement or worsening of disability has not been reported.

## DISCUSSION

This systematic review showed that DECT images are reliably interpreted to a great extent with intrarater ICCs from 0.86 to 1.00. The stage of gout (ie, early, middle, or late) does not influence this level of reliability. DECT overall has very good sensitivity and specificity in established gout when compared with joint aspiration, with ranges from 0.78 to 0.89 and 0.84 to 1.00, respectively. DECT also performed very well against clinical criteria, with a pooled sensitivity and specificity of 0.81 (95% CI 0.77-0.86) and 0.91 (95% CI 0.85-0.95).<sup>19</sup> Singh and colleagues<sup>34</sup> reported that DECT of the ankles and feet performed as well as, or better than, DECT of multiple locations, such as the ankles and the feet and knees combined. This is consistent with Mallinson et al<sup>53</sup> who showed that DECT is most likely to be abnormal at the ankles and feet. Further work should confirm whether DECT of the feet and ankles alone is preferred over scanning additional areas that are involved clinically.

DECT in early gout has reduced sensitivity but its specificity is preserved, as compared to established gout. Lee et al<sup>31</sup> reported sensitivities from 0.51 and 0.53 for 2 readers, with early gout defined by the absence of signs of established gout or lack of ULT. Zhang et al<sup>30</sup> defined early gout as less than 1 year from first symptoms, with DECT sensitivities of 0.27 for early gout, 0.75 for middle gout, and 0.90 for late gout. Zhang et al<sup>30</sup> suggested that ultrasound had better sensitivity than DECT in early gout, with values of 0.67 and 0.27, respectively, using the gold-standard clinical procedure of joint aspiration. Shang and colleagues<sup>18</sup> showed that DECT of early gout cases had a pooled sensitivity of 0.75 (95% CI 0.60-0.86) and a pooled specificity of 0.85 (95% CI 0.75-0.91), whereas ultrasound had a pooled sensitivity of 0.93 (95% CI 0.72-0.99) and a pooled specificity of 0.80 (95% CI 0.71-0.86). It may be beneficial for future studies of early gout to use a standard definition, such as time from first symptoms or the absence of clinical signs and symptoms. More head-to-head studies of DECT and ultrasound in early gout are needed to confirm benefits. Ahn and colleagues<sup>54</sup> suggested that DECT is less sensitive in early gout since MSU crystals in synovial fluid have a low density, reducing resolution. To illustrate this, Ahn et al<sup>54</sup> collected patient-derived solid and liquid tophi from 3 patients at surgery. DECT did not detect urate deposition in liquid tophi at any urate concentration, whereas solid tophi were easily detected.<sup>54</sup> Based on the lower sensitivity of DECT in early gout and considering that more studies of ultrasound in early gout are needed, when symptoms are less than 2 years in duration, it is recommended that clinicians aspirate joints preferentially, including when a DECT scan is negative.

Clinical tophi predict excess CV and all-cause mortality,<sup>11,40</sup> and DECT scans also predict<sup>41</sup> CV and all-cause mortality in prospective cohorts. Since up to 50.0% of patients without clinical tophi or abnormal serum urates have abnormal DECT scans,

confirming the mortality relationship to DECT is important. DECT was shown to be associated with CV risk scores in 5 out of 6 studies examining this relationship.<sup>8,10,41-43</sup>

Clinical tophi correlate with hand disability.<sup>39</sup> We did not find studies on the relationship of DECT volumes and disability for the hands, feet, ankles, or knees, although a relationship seems probable. These studies should be performed.

A relationship between DECT volume and future gout flares was found in 4 studies<sup>8,12,45,46</sup>; DECT volume predicted flares at 6 months<sup>46</sup> and 2 years.<sup>45</sup> No studies were found on DECT volume and its relationship to chronic gouty arthropathy.

This systematic review found DECT volume to be very sensitive to change with effective ULT, supporting DECT use in clinical studies and in the clinic as an outcome measure. The minimum important volume of DECT is tentatively set at 1.00 cm<sup>3</sup>, a value that seems to predict death, CV risk factor burden, and future gout flare risk; however, this threshold only considers DECT volume in the feet and ankles and not in areas such as the hands, wrists, and knees. Further work on defining the minimum important value should be undertaken.

To the best of our knowledge, there are no prior systematic reviews of DECT volume and its prognostic ability. Still, this systematic review has several limitations. The conclusions are limited by the quantity and quality of the current literature. Most of the literature relating to DECT reliability has shown it to be excellent. The diagnostic performance of DECT and ultrasound in early gout requires more study where DECT sensitivity appears lower. The prognostic value of DECT abnormalities in the absence of clinical tophi is not fully defined but is important, as up to 50.0% of patients with gout have an abnormal DECT scan without clinical tophi or abnormal serum urate levels. We found limited literature on the relationship of DECT to disability. We also found limited literature on the minimum important change in DECT.

A large, properly powered, prospective cohort study should be performed that includes early and established gout, patients with and without clinical tophi, patients with and without abnormal DECT scans, both males and females, and patients with and without controlled hyperuricemia to better understand DECT's prognostic potential. DECT scans of the feet, ankles, knees, hands, and wrists could inform on near-term outcomes, such as joint pain (ie, chronic pain and acute flares) and hand and foot disability. Better characterization of the relationship of DECT-measured urate volume with mortality would be welcome; a large New Zealand gout cohort saw separation in mortality rates between participants with and without tophi in as early as 1 year.<sup>11</sup> Ideally, DECT and ultrasound would be contrasted further to better understand their respective prognostic abilities.

DECT is a promising prognostic tool in gout. It has excellent reliability with good diagnostic test performance in established gout. It is very sensitive to change with effective ULTs, supporting its use as a clinical outcome measure. DECT appears to have a reduced sensitivity in early gout, and joint aspiration should be undertaken preferentially when disease duration is less than 2 years, including when DECT is negative. Based on



current evidence showing that DECT volumes predict mortality and gout flares, DECT should be used to stage patients with gout, especially in established disease, as 50.0% of patients have abnormal DECT scans with normal serum urate levels and no clinical tophi.

## ACKNOWLEDGMENT

Editorial assistance was provided by Amy Cohen, PhD, a Horizon employee.

## REFERENCES

1. Kuo C-F, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence, and risk factors. *Nat Rev Rheumatol* 2015;11:649-62.
2. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016. *Arthritis Rheumatol* 2019;71:991-9.
3. Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheumatol* 2015;67:2557-68.
4. Taylor WJ, Fransen J, Dalbeth N, et al. Diagnostic arthrocentesis for suspicion of gout is safe and well tolerated. *J Rheumatol* 2016;43:150-3.
5. Dalbeth N, Doyle AJ. Imaging tools to measure treatment response in gout. *Rheumatology* 2018;57:i27-34.
6. Dalbeth N, Choi HK. Dual-energy computed tomography for gout diagnosis and management. *Curr Rheumatol Rep* 2013;15:301.
7. Khanna P, Johnson RJ, Marder B, LaMoreaux B, Kumar A. Systemic urate deposition: an unrecognized complication of gout? *J Clin Med* 2020;9:3204.
8. Gamala M, Linn-Rasker SP, Nix M, et al. Gouty arthritis: decision-making following dual-energy CT scan in clinical practice, a retrospective analysis. *Clin Rheumatol* 2018;37:1879-84.
9. Klauser AS, Halpern EJ, Strobl S, et al. Dual-energy computed tomography detection of cardiovascular monosodium urate deposits in patients with gout. *JAMA Cardiol* 2019;4:1019-28.
10. Pascart T, Ramon A, Ottaviani S, et al. Association of specific comorbidities with monosodium urate crystal deposition in urate-lowering therapy-naive gout patients: a cross-sectional dual-energy computed tomography study. *J Clin Med* 2020;9:1295.
11. Vincent ZL, Gamble G, House M, et al. Predictors of mortality in people with recent-onset gout: a prospective observational study. *J Rheumatol* 2017;44:368-73.
12. Dalbeth N, Nicolaou S, Baumgartner S, Hu J, Fung M, Choi HK. Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol. *Ann Rheum Dis* 2018;77:364-70.
13. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results, and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. *JAMA* 1994;271:703-7.
14. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017;358:j4008.
15. Carroll LJ, Cassidy JD, Peloso PM, et al. Methods for the best evidence synthesis on neck pain and its associated disorders: the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders. *Spine* 2008;33:S33-8.
16. Gittinger FP, Lemos M, Neumann JL, et al. Interrater reliability in the assessment of physiotherapy students. *BMC Med Educ* 2022;22:186.
17. Tugwell P, Boers M, D'Agostino MA, et al. Updating the OMERACT Filter: implications of Filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity. *J Rheumatol* 2014;41:1000-4.
18. Shang J, Zhou LP, Wang H, Liu B. Diagnostic performance of dual-energy CT versus ultrasonography in gout: a meta-analysis. *Acad Radiol* 2022;29:56-68.
19. Gamala M, Jacobs JWG, van Laar JM. The diagnostic performance of dual energy CT for diagnosing gout: a systematic literature review and meta-analysis. *Rheumatology* 2019;58:2117-21.
20. Yu Z, Mao T, Xu Y, et al. Diagnostic accuracy of dual-energy CT in gout: a systematic review and meta-analysis. *Skeletal Radiol* 2018;47:1587-93.
21. Chen J, Liao M, Zhang H, Zhu D. Diagnostic accuracy of dual-energy CT and ultrasound in gouty arthritis: a systematic review. *Z Rheumatol* 2017;76:723-9.
22. Lee YH, Song GG. Diagnostic accuracy of dual-energy computed tomography in patients with gout: a meta-analysis. *Semin Arthritis Rheum* 2017;47:95-101.
23. Newberry SJ, FitzGerald JD, Motala A, et al. Diagnosis of gout: a systematic review in support of an American College of Physicians clinical practice guideline. *Ann Intern Med* 2017;166:27-36.
24. Ogdie A, Taylor WJ, Weatherall M, et al. Imaging modalities for the classification of gout: systematic literature review and meta-analysis. *Ann Rheum Dis* 2015;74:1868-74.
25. Bayat S, Aati O, Rech J, et al. Development of a dual-energy computed tomography scoring system for measurement of urate deposition in gout. *Arthritis Care Res* 2016;68:769-75.
26. Shi D, Xu JX, Wu HX, Wang Y, Zhou QJ, Yu RS. Methods of assessment of tophus and bone erosions in gout using dual-energy CT: reproducibility analysis. *Clin Rheumatol* 2015;34:755-65.
27. Choi HK, Burns LC, Shojania K, et al. Dual energy CT in gout: a prospective validation study. *Ann Rheum Dis* 2012;71:1466-71.
28. Pascart T, Grandjean A, Norberciak L, et al. Ultrasonography and dual-energy computed tomography provide different quantification of urate burden in gout: results from a cross-sectional study. *Arthritis Res Ther* 2017;19:171.
29. Dalbeth N, Aati O, Gao A, et al. Assessment of tophus size: a comparison between physical measurement methods and dual-energy computed tomography scanning. *J Clin Rheumatol* 2012;18:23-7.
30. Zhang B, Yang M, Wang H. Diagnostic value of ultrasound versus dual-energy computed tomography in patients with different stages of acute gouty arthritis. *Clin Rheumatol* 2020;39:1649-53.
31. Lee SK, Jung JY, Jee WH, Lee JJ, Park SH. Combining non-contrast and dual-energy CT improves diagnosis of early gout. *Eur Radiol* 2019;29:1267-75.
32. Shang J, Li XH, Lu SQ, Shang Y, Li LL, Liu B. Gout of feet and ankles in different disease durations: diagnostic value of single-source DECT and evaluation of urate deposition with a novel semi-quantitative DECT scoring system. *Adv Rheumatol* 2021;61:36.
33. Kravchenko D, Karakostas P, Kuetting D, et al. The role of dual energy computed tomography in the differentiation of acute gout flares and acute calcium pyrophosphate crystal arthritis. *Clin Rheumatol* 2022;41:223-33.
34. Singh JA, Budzik JF, Becce F, Pascart T. Dual-energy computed tomography vs ultrasound, alone or combined, for the diagnosis of gout: a prospective study of accuracy. *Rheumatology* 2021;60:4861-7.
35. Dalbeth N, Aati O, Kalluru R, et al. Relationship between structural joint damage and urate deposition in gout: a plain radiography and



- dual-energy CT study. *Ann Rheum Dis* 2015;74:1030-6.
36. Shi D, Chen JY, Wu HX, et al. Relationship between urate within tophus and bone erosion according to the anatomic location of urate deposition in gout: a quantitative analysis using dual-energy CT volume measurements. *Medicine* 2019;98:e18431.
  37. Pecherstorfer C, Simon D, Unbehend S, et al. A detailed analysis of the association between urate deposition and erosions and osteophytes in gout. *ACR Open Rheumatol* 2020;2:565-72.
  38. Yokose C, Dalbeth N, Wei J, et al. Radiologic evidence of symmetric and polyarticular monosodium urate crystal deposition in gout - a cluster pattern analysis of dual-energy CT. *Semin Arthritis Rheum* 2020;50:54-8.
  39. Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM. Tophaceous joint disease strongly predicts hand function in patients with gout. *Rheumatology* 2007;46:1804-7.
  40. Perez-Ruiz F, Martínez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JJ, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. *Ann Rheum Dis* 2014;73:177-82.
  41. Marty-Ané A, Norberciak L, Andrés M, et al. Crystal deposition measured with dual-energy computed tomography: association with mortality and cardiovascular risks in gout. *Rheumatology* 2021;60:4855-60.
  42. Gamala M, Jacobs JWG, Linn-Rasker SP, et al. Cardiovascular risk in patients with new gout diagnosis: is monosodium urate volume at ankles and feet on dual-energy CT associated with previous cardiovascular events? *Clin Exp Rheumatol* 2020;38:763-6.
  43. Lee KA, Ryu SR, Park SJ, Kim HR, Lee SH. Assessment of cardiovascular risk profile based on measurement of tophus volume in patients with gout. *Clin Rheumatol* 2018;37:1351-8.
  44. Pascart T, Capon B, Grandjean A, et al. The lack of association between the burden of monosodium urate crystals assessed with dual-energy computed tomography or ultrasonography with cardiovascular risk in the commonly high-risk gout patient. *Arthritis Res Ther* 2018;20:97.
  45. Dalbeth N, Billington K, Doyle A, et al. Effects of allopurinol dose escalation on bone erosion and urate volume in gout: a dual-energy computed tomography imaging study within a randomized, controlled trial. *Arthritis Rheumatol* 2019;71:1739-46.
  46. Pascart T, Grandjean A, Capon B, et al. Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study: MSU burden and risk of gout flare. *Arthritis Res Ther* 2018;20:210.
  47. Araujo EG, Bayat S, Petsch C, et al. Tophus resolution with pegloticase: a prospective dual-energy CT study. *RMD Open* 2015;1:e000075.
  48. Modjinou DV, Krasnokutsky S, Gyftopoulos S, et al. Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking. *Clin Rheumatol* 2017;36:2101-7.
  49. Chui CSK, Choi AKY, Lam MMY, et al. Volumetric reduction and dissolution prediction of monosodium urate crystal during urate-lowering therapy – a study using dual-energy computed tomography. *Mod Rheumatol* 2021;31:875-84.
  50. Uhlig T, Eskild T, Karoliussen LF, et al. Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study. *Rheumatology* 2022;61:SI81-5.
  51. Sun Y, Chen H, Zhang Z, et al. Dual-energy computed tomography for monitoring the effect of urate-lowering therapy in gouty arthritis. *Int J Rheum Dis* 2015;18:880-5.
  52. Rajan A, Aati O, Kalluru R, et al. Lack of change in urate deposition by dual-energy computed tomography among clinically stable patients with long-standing tophaceous gout: a prospective longitudinal study. *Arthritis Res Ther* 2013;15:R160.
  53. Mallinson PI, Reagan AC, Coupal T, Munk PL, Ouellette H, Nicolaou S. The distribution of urate deposition within the extremities in gout: a review of 148 dual-energy CT cases. *Skeletal Radiol* 2014;43:277-81.
  54. Ahn SJ, Zhang D, Levine BD, et al. Limitations of dual-energy CT in the detection of monosodium urate deposition in dense liquid tophi and calcified tophi. *Skeletal Radiol* 2021;50:1667-75.